MRNA Moderna Inc.

22.7
+0.1  (+0%)
Previous Close 22.6
Open 22.65
Price To Book 5.16
Market Cap 7468374229
Shares 329,003,270
Volume 475,913
Short Ratio
Av. Daily Volume 892,518

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1 completed.
VEGF-A(AZD8601)
Myocardial ischemia
Phase 1 completed.
mRNA-2416
Solid tumors, lymphoma
Phase 1 updated data due at ASCO June 1, 2019, 1:15 PM
mRNA-4157 - KEYNOTE-603
Personalized cancer vaccine
Phase 1 completed.
mRNA-1388
Chikungunya vaccine
Phase 1 completed.
mRNA-1851
Influenza vaccine
Phase 1 completed.
mRNA-1440
Influenza vaccine
Phase 1 ongoing.
mRNA-1653
Human Metapneumovirus and Human Parainfluenza Infection (hMPV+PIV3 vaccine)
Phase 1 ongoing.
mRNA-1647
CMV vaccine (Cytomegalovirus Infection)
Development has been paused - May 8, 2019.
mRNA-1777
RSV vaccine
Phase 1/2 trial planned.
mRNA-3704
Methylmalonic Acidemia (MMA)
Phase 1 dosing has commenced - noted January 8, 2019.
mRNA-2752
Solid tumors, lymphoma
Phase 1 initiation of dosing announced February 5, 2019.
mRNA-1944
Chikungunya Virus Infection
Phase 1 data to be presented at ASCO June 1, 2019, 8am.
mRNA-4650
Autologous Cancer